HCPCS Code J1810: droperidol and fentanyl citrate injection (deleted)

Key takeaways

HCPCS Code J1810 described the injection of droperidol and fentanyl citrate, up to 2 ml ampule. The combination agent was used for procedural sedation and anesthesia induction.

CMS deleted J1810 effective March 31, 2025, so any claim carrying the code today will be denied by Medicare and most commercial payers.

There is no single replacement code. Report droperidol and fentanyl citrate separately, and confirm each code against the CMS HCPCS file for the year of service.

Practice management software like Pabau validates the fields each insurer requires before a claim goes out, then tracks its status through to payment.

HCPCS Code J1810: definition and code details

HCPCS Code J1810 described the injection of droperidol and fentanyl citrate, up to 2 ml ampule. It sat in the HCPCS Level II J-code series. That series covers drugs administered in a clinical setting and billed to Medicare Part B or a commercial payer. CMS deleted the code effective March 31, 2025. Any claim submitted with J1810 after that date is rejected as an invalid code. That holds whether it surfaced on an old remittance, in an audit, or in a resubmission queue.

The table below captures the essential metadata for HCPCS Code J1810.

CMS maintains the HCPCS Level II code set and revises the drug and biological J-codes quarterly. Per CMS’s HCPCS overview, a deleted code drops out of the active file on its termination date. Payers stop honoring it from that date, and it does not return in a later release.

Why HCPCS Code J1810 was deleted

CMS deletes a HCPCS code when the product behind it leaves the market, when more specific codes replace it, or when reporting practice changes. J1810 went for the first of those reasons.

Innovar, the fixed-ratio droperidol and fentanyl citrate ampule, is listed as discontinued from marketing in the FDA Orange Book. With no marketed product left to report, CMS retired the code in its fourth-quarter 2024 HCPCS update, with a termination date of March 31, 2025. Providers who still administer either drug report it under that drug’s own active J-code.

• No marketed combination product: the fixed-ratio ampule is no longer sold in the US. The combination code describes a product nobody can buy.
• Drug-level reporting instead: droperidol and fentanyl citrate each carry their own active J-code, so each goes on its own claim line.
• Quarterly revisions: CMS updates the drug and biological J-codes four times a year, so a code can end mid-year rather than on January 1.
• No grace period: the termination date is a hard cutoff, and payer claim editors reject the code from that date forward.

Providers who keep submitting a deleted code collect automatic rejections, and a repeating pattern can draw an audit. Sorting those rejections by cause is the first step in denial management.

Clinical context: what was J1810 used for?

Droperidol and fentanyl citrate together produced a clinical state called neuroleptanalgesia. Patients became sedated and analgesic while remaining conscious enough to cooperate with simple commands. This made the combination useful for minor surgical procedures, diagnostic imaging requiring patient cooperation, and anesthesia induction prior to general anesthesia.

The combination product, sold as Innovar, contained 0.05 mg of fentanyl and 2.5 mg of droperidol per mL. Billing under J1810 covered up to 2 ml of that ampule. The code appeared most often in outpatient surgical and anesthesia billing while it was active.

• Droperidol: A butyrophenone antipsychotic used for its sedative and antiemetic properties in procedural settings.
• Fentanyl citrate: A potent synthetic opioid analgesic. Administered parenterally for rapid pain relief during procedures.
• Clinical application: Neuroleptanalgesia, sedation for minor procedures, anesthesia adjunct, pre-procedural anxiolysis.
• DEA scheduling: Fentanyl is a Schedule II controlled substance under DEA regulations. Providers should maintain compliant controlled-substance documentation regardless of the HCPCS code used for billing.

Billing staff reviewing old records should read J1810 as a description of the service, not as a data-entry mistake. The injection happened as documented. Only the code used to report it has expired.

Crosswalk and replacement codes for J1810

There is no single direct replacement for HCPCS Code J1810. Because J1810 was a combination code, billers now need to report each drug component separately. The correct approach is to verify the currently active J-code for each drug in the CMS HCPCS annual file before submitting any claim.

The table below shows the typical crosswalk approach based on available HCPCS data. Descriptors and statuses change with each release. Verify these codes against the current HCPCS code set via AAPC Codify or the CMS release before submitting any claim.

The codes above are commonly cited alternatives, not formally CMS-designated replacements for J1810. Confirm each one is active in the year of service before submitting. Where neither specific code applies, J3490 (injection, drug, unclassified) can work as a payer-specific fallback. Many payers require prior authorization or supporting documentation when J3490 is used.

The chart below sets out which code to reach for, and the filing window that decides whether a corrected claim is worth submitting.

Medicare billing and reimbursement for J1810

Medicare will deny any claim submitted with HCPCS Code J1810. The code is deleted and not recognized in the Medicare Physician Fee Schedule or the Medicare Part B drug payment system. This applies to all Medicare Administrative Contractor (MAC) jurisdictions nationwide.

Historical Medicare reimbursement rates for J1810 are no longer published in active fee schedule data. Because the code is removed from the CMS HCPCS file, it does not appear in the CMS Physician Fee Schedule lookup tool. Any rate figures found in third-party reference databases reflect historical data only and have no current billing value.

For services rendered while J1810 was still active, three questions decide whether a corrected claim is worth filing:

• Is a correction appropriate for this encounter, or was the service already paid under another code?
• Has the payer’s timely filing limit passed for that date of service?
• Was the crosswalk code you plan to use active on that date?

Billing guidelines and coding notes

Practical steps for billing staff encountering J1810 on claims or in a billing queue:

1. Stop the claim. Do not submit or resubmit any claim with J1810 as the procedure code. It will deny.
2. Identify the date of service. Crosswalk code selection depends on which codes were active in the year the service was provided, not today’s code set.
3. Pull the CMS HCPCS file for that year. CMS archives annual HCPCS Level II files. Identify the active code for droperidol and the active code for fentanyl citrate for the service date.
4. Check timely filing limits. Medicare allows one year from the date of service. Most commercial payers allow 90 to 180 days. A claim filed after the window closes will deny however correct the coding is.
5. Submit a corrected claim. Use the appropriate crosswalk codes for each drug component. Attach a note or supplemental documentation explaining the original code error and the correction.
6. Document the review. Keep a record of the code change rationale. If the practice is audited, documentation showing the correction was deliberate and code-compliant protects against fraud findings.

Catching a retired code before submission costs a fraction of working the denial afterward. Scrub your active code library against the current CMS HCPCS file each quarter. Drug codes deserve the closest look, since they change four times a year.

Payer-specific coverage policies

Every major payer class handles deleted HCPCS codes the same way: automatic denial. The table below summarizes what to expect when J1810 appears on a claim submitted to any payer today.

For Medicare, check the Local Coverage Determination or National Coverage Determination that applies to the replacement code before submitting. Commercial payers set their own drug fee schedules and often give different instructions for unclassified drug codes. Their provider manual or provider relations line will say which active code they expect. Keep a copy of that guidance on file whenever a code changes mid-claim.

Related J-codes for drug injections

Billers in anesthesia, procedural sedation, or pain management will meet related active J-codes alongside J1810 in historical records. The table below lists the ones referenced most often in adjacent clinical contexts. Verify current status against the CMS HCPCS release before billing.

Confirm every status in the table above against the current CMS HCPCS release. Drug and biological J-codes are revised quarterly, so a code active this quarter can be terminated in the next.

Where practice management software helps after a J1810 denial

A retired code reaches the billing queue by a few predictable routes:

• A superbill template nobody has reviewed since the code was active.
• A copy-paste from a previous encounter’s charge line.
• A billing system running a stale drug code library.

Each route ends the same way. The claim denies, and someone reworks it by hand.

Practice management software keeps that rework in one place. Pabau’s claims management software checks the fields each insurer requires before a claim is sent. It then tracks the claim’s status next to the schedule and the clinical note behind it. Billing staff review, correct, and resubmit without moving between separate systems. It will not tell you that a HCPCS code has been retired, so the quarterly code library check stays a manual task.

For a practice working through a backlog of historical claims, most of the job is matching each claim to the documentation behind it. Reviewing denials by code type then shows whether retired codes are a recurring problem on particular service lines or providers.

Keep every claim moving in one place

Pabau’s claims management tools check insurer-required fields before submission and track each claim’s status next to the appointment and note it came from.

Book a demo

Conclusion

J1810 ended on March 31, 2025, and no payer will reimburse it now. The correction itself is mechanical. Report droperidol and fentanyl citrate on separate lines. Confirm both codes in the CMS HCPCS file for the service year, then file inside the payer’s timely filing window.

The trade-off worth remembering is timing rather than coding. A corrected claim filed inside the window is worth the rework. One filed outside it is a write-off, however correct the codes are.

Keeping this off next quarter’s denial list is a process question more than a coding one. Pabau helps billing teams work through denial codes with claim tracking and correction built into the platform your practice already runs. Book a demo to see how your team would handle a J1810 correction end to end.

Continue your research

Need to understand how medical billing works from the ground up? What is medical billing explains the full claim lifecycle, from charge capture to payment posting.

Working through a pile of denied claims? Denial management in healthcare covers the most common denial categories and how to build a systematic appeal workflow.

Evaluating billing software for your practice? Best medical billing software in the US breaks down the leading options by practice size and specialty.

Frequently asked questions